Skip to main content
. 2015 Dec 7;7(3):3440–3452. doi: 10.18632/oncotarget.6497

Figure 6. The EZH2 small molecule inhibitor GSK126 sensitizes CRPC cells to CPT-induced apoptotic death and enhances CPT-mediated inhibition of cell growth.

Figure 6

A. C4-2 CRPC cells were treated with vehicle (DMSO), CPT (100 nM), GSK126 (10 μM) or both drugs. Cell viability was measured at different time points after treatment using MTS assays. B–C. C4-2 CRPC cells were treated as in (A) At 48 h after treatment cells were harvested for western blot analysis with indicated antibodies (B) and measurement of caspase-3 activity (C) ERK2 was used as a loading control. Data are means ± S.D. from 3 replicates. *P < 0.01. D. C4-2 CRPC cells were treated with CPT (250 nM), GSK126 (20 μM) or both. At 48 h after treatment, cells were collected and fixed with 70% ethanol and subject to sub-G1 analysis flow cytometry. PI, propidium iodide. Experiments were repeated two more times and similar results were obtained. E–F. C4-2 cells infected with indicated shRNAs were injected s.c. into the right flank of NSG mice (n = 5). The tumor volume of each xenograft at each time point (E) and tumors at the end of treatment (F) are shown. Error bars, SD from five tumors. *P < 0.05.